Psyga Bio

Psyga Bio is an advanced biotechnology company focused on the research, development, and commercialization of proprietary therapeutics derived from psychedelic and functional mushrooms. The company's pipeline includes seven approved Phase 2a human clinical trials targeting severe mental health disorders, treatment-resistant depression, post-traumatic stress disorder (PTSD), anorexia, and addiction. Psyga Bio operates a licensed, GMP-ready pharmaceutical manufacturing facility designed for the cultivation, extraction, isolation, and formulation of pharmaceutical-grade botanical and synthetic psilocybin, ibogaine, and other psychedelic active pharmaceutical ingredients (APIs). Additionally, the company possesses a proprietary library of over 250 unique, biologically active mushroom strains. In June 2026, Psyga Bio was acquired by XTL Biopharmaceuticals, establishing a leading public psychedelic biotechnology platform.